Sermorelin for Pediatric Growth Hormone Deficiency: Who Qualifies and What the Evidence Actually Shows

What Sermorelin Is and Why "Off-Label" Matters Here

Sermorelin acetate is a 29-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and secrete the body's own growth hormone (GH) rather than supplying exogenous GH directly. That mechanism is the central reason it is sometimes preferred over recombinant human GH (somatropin) in children who still have residual pituitary function.

The original branded product, Geref (Serono), received FDA approval in 1997 specifically for the long-term treatment of idiopathic GHD in prepubertal children. The manufacturer withdrew Geref from the US market in 2002 for commercial, not safety, reasons. Since then, sermorelin has been available only through compounding pharmacies. Because compounded sermorelin does not hold an active FDA approval for pediatric GHD, any current use in children is technically off-label. Parents and clinicians alike should understand that distinction before starting therapy.

Off-label does not mean experimental in a vacuum. Pediatric endocrinologists with experience in hypothalamic-pituitary disorders do prescribe compounded sermorelin for selected children, drawing on the original Geref trial data and on the well-characterized GHRH physiology. But the evidence base is thinner than for somatropin, and the compounding pharmacy supply chain adds a quality-control variable that branded drugs do not carry.

How GHD Is Diagnosed Before Any Treatment Decision

Before a child can be considered for sermorelin, the diagnosis of GHD must be established through a structured workup. Sermorelin is not appropriate for children who are simply shorter than their peers without a documented hormonal deficiency.

Growth Velocity and Auxological Screening

The first signal is almost always a fall-off on the growth chart. A height below the third percentile for age and sex, or a growth velocity more than 1.5 standard deviations below the mean for age, warrants investigation. CDC growth charts stratified by sex are the standard reference in the United States.

For girls, this step requires sex-specific charts from the outset. A girl growing along the second percentile may look identical on an unisex chart to a boy at the same percentile, but the differential diagnosis differs substantially. Girls require earlier consideration of Turner syndrome (affecting approximately 1 in 2,000 live female births) and other X-chromosome conditions that cause short stature independently of GH status.

Bone Age Radiograph

A left-hand and wrist X-ray read against the Greulich-Pyle atlas estimates skeletal maturity. A bone age significantly delayed relative to chronological age supports a GH-axis problem but is not diagnostic alone. Open growth plates are also a prerequisite for any GH-axis therapy, including sermorelin. Once the epiphyses are fused, the drug cannot produce linear growth.

IGF-1 and IGFBP-3 Measurement

Insulin-like growth factor 1 (IGF-1) is the most practical serum biomarker of GH secretion. A low IGF-1 standard deviation score (SDS) for age and Tanner stage raises suspicion for GHD. IGF-binding protein 3 (IGFBP-3) adds specificity, particularly in very young children where IGF-1 assays have wider reference ranges.

One detail that is frequently glossed over in general pediatric references: girls have measurably higher IGF-1 levels than boys at equivalent Tanner stages, particularly during mid-puberty. A lab result that looks borderline low for a boy may represent a more significant deficit in a girl. Clinicians should use sex-stratified IGF-1 normative data rather than combined-sex references when interpreting results in girls.

GH Stimulation Testing

Single random GH levels are essentially useless for diagnosing GHD because GH is secreted in pulses. Standard practice requires two pharmacological GH stimulation tests using agents such as arginine, clonidine, glucagon, or insulin-induced hypoglycemia. The classic US diagnostic threshold is a peak GH below 10 ng/mL on both tests in a child primed with sex steroids (estrogen for girls, testosterone for boys) to avoid false-positive results from physiological hyposecretion seen in prepubertal children.

The 10 ng/mL cutoff is consensus-based, not derived from a precise physiological threshold. The Endocrine Society 2016 clinical practice guideline on GHD acknowledges that no single cutoff has perfect sensitivity and specificity, and it recommends interpreting stimulation results alongside all auxological and biochemical data.

MRI of the Hypothalamic-Pituitary Axis

Any child with confirmed or suspected GHD should have an MRI of the brain focused on the hypothalamus and pituitary before treatment. Structural causes, including craniopharyngioma, pituitary hypoplasia, and ectopic posterior pituitary, must be excluded. An MRI also helps predict whether the pituitary can respond to GHRH stimulation, which is essential information when considering sermorelin specifically.

Why Pituitary Functional Reserve Determines Sermorelin Eligibility

This is the single most important patient-selection criterion for sermorelin specifically, and it is the point where sermorelin diverges from somatropin in clinical decision-making.

Somatropin supplies GH exogenously. It works regardless of whether the child's pituitary is functional. Sermorelin works by stimulating the child's own pituitary to release GH. A child whose pituitary has been destroyed, surgically removed, or severely damaged by a tumor or radiation will not respond to sermorelin with meaningful GH release.

A practical framework for assessing pituitary reserve before sermorelin:

1. GHRH stimulation test response. An acute GHRH stimulation test (1 mcg/kg IV) can directly assess pituitary responsiveness. A GH peak above 10 ng/mL after GHRH suggests intact pituitary somatotroph function and a hypothalamic origin for the GHD. This result makes sermorelin a biologically rational choice.
2. MRI morphology. A structurally normal or mildly hypoplastic pituitary without mass lesions supports preserved somatotroph capacity.
3. History of cranial radiation or surgery. Children with prior craniopharyngioma resection or cranial irradiation affecting the hypothalamic-pituitary axis are generally poor sermorelin candidates. Their deficit is often at the pituitary level, and somatropin is the appropriate therapy.
4. Idiopathic GHD phenotype. Children with idiopathic GHD and a characteristic MRI pattern (small anterior pituitary, ectopic posterior pituitary, thin or absent stalk) may still have residual somatotroph cells that respond to GHRH stimulation. These children were the original population in the Geref clinical trials.

Female-Specific Patient Selection Considerations

Girls presenting with short stature and suspected GHD face a more complex diagnostic algorithm than boys, and several female-specific conditions must be systematically addressed before sermorelin is considered.

Turner Syndrome Must Be Excluded First

Turner syndrome (45,X or mosaic variants) is the most common genetic cause of short stature in girls and affects approximately 1 in 2,000 female births. Girls with Turner syndrome often have low GH stimulation test responses, making GHD appear to be the diagnosis when it is not. A karyotype is mandatory in any girl with unexplained short stature before committing to GH-axis treatment. Turner syndrome has its own FDA-approved GH dosing protocol and is not a sermorelin indication.

SHOX Gene Haploinsufficiency

SHOX (short stature homeobox gene) deficiency causes disproportionate short stature with skeletal dysplasia features. It can mimic GHD on growth charts. Molecular testing for SHOX deletions or mutations should be considered in girls with disproportionate limb shortening before attributing short stature to GH deficiency alone.

Hypothyroidism

Untreated or undertreated primary hypothyroidism suppresses GH secretion and can cause a reversible form of secondary GHD. Girls are more likely than boys to develop autoimmune thyroid disease. TSH and free T4 should be measured before any GH-axis workup is interpreted. If hypothyroidism is found and treated, GH stimulation testing should be repeated after thyroid status is normalized.

Premature Adrenarche and PCOS in Adolescent Girls

In adolescent girls, premature adrenarche and early or frank polycystic ovary syndrome (PCOS) can alter IGF-1 levels. PCOS is associated with elevated IGF-1 and IGF-1 bioavailability in some girls, which could mask a concurrent GHD on biomarker testing. Adolescent girls with irregular cycles and short stature need a more comprehensive endocrine workup before sermorelin or somatropin is prescribed.

Who Is and Is Not a Candidate for Off-Label Sermorelin

A clear-eyed summary belongs here. Sermorelin is not for every child with short stature or even every child with confirmed GHD.

Likely appropriate candidates (all criteria should be met):

• Confirmed GHD by two pharmacological stimulation tests with peak GH <10 ng/mL after sex-steroid priming
• Idiopathic or hypothalamic-origin GHD with intact or partially intact pituitary function on GHRH stimulation
• Open growth plates on bone age radiograph
• No structural pituitary mass on MRI
• Normal thyroid function
• Karyotype confirming 46,XX in girls (Turner syndrome excluded)
• Family informed and accepting of the off-label, compounded-pharmacy context

Not appropriate candidates:

• Children with GHD caused by pituitary destruction, craniopharyngioma resection, or cranial irradiation
• Girls with Turner syndrome (use somatropin per approved Turner dosing)
• Children with fused growth plates
• Children with active malignancy (GH-axis stimulation is contraindicated during active cancer treatment per Endocrine Society guidelines)
• Pregnant adolescents (see pregnancy section below)

Dosing and Administration in Pediatric Patients

Sermorelin for pediatric GHD is given as a daily subcutaneous injection, typically at bedtime to align with the physiological nocturnal GH surge. The dose used in the original Geref trials was 0.03 mg/kg/day subcutaneously once daily. Compounded sermorelin preparations attempt to replicate this dose, but concentration, purity, and sterility standards vary by pharmacy.

Monitoring during therapy includes:

• IGF-1 every 3 to 6 months, with dose adjustments to maintain IGF-1 SDS between 0 and +2 for age and sex
• Growth velocity measurement every 6 months (a response of at least 2 cm/year above pretreatment velocity is generally considered meaningful)
• Bone age radiograph annually to assess remaining growth potential
• Fasting glucose and insulin periodically, because GHRH-induced GH elevation reduces insulin sensitivity

For girls entering or progressing through puberty, the IGF-1 target range needs to be recalibrated at each Tanner stage because sex hormone-driven IGF-1 rises are physiological and should not be confused with supraphysiological drug effect.

Sermorelin Versus Somatropin: The Practical Comparison for Families

Parents frequently ask how sermorelin compares to somatropin (recombinant GH). The honest answer is that somatropin has a substantially larger evidence base for pediatric GHD. Randomized trials including the NCGS (National Cooperative Growth Study) followed thousands of children on somatropin for years and established height velocity, adult height, and safety data that compounded sermorelin simply cannot match.

Sermorelin's theoretical advantages are that it preserves the natural pulsatile pattern of GH secretion, carries a self-limiting mechanism (pituitary saturation), and may be less likely to produce supraphysiological IGF-1 levels. These advantages are biologically plausible. They are not proven in long-term randomized comparisons against somatropin in children.

Somatropin is FDA-approved for pediatric GHD. Compounded sermorelin is not. For most children with confirmed GHD, somatropin remains the Endocrine Society guideline-recommended first-line treatment. A family choosing compounded sermorelin should do so with a pediatric endocrinologist who is transparent about the evidence differences and who has a plan to switch to somatropin if growth response is inadequate within six months.

Pregnancy, Lactation, and Contraception: Required Section for Adolescent Girls on Sermorelin

Any article on a drug that may be prescribed to adolescent girls must address reproductive safety directly.

Pregnancy

Sermorelin has not been studied in human pregnancy. Based on animal data and the general principle that hormonal axis manipulation during organogenesis carries unknown risks, sermorelin should be considered contraindicated in pregnancy. There is no FDA pregnancy category designation for the current compounded form because it does not hold an active NDA. The original Geref prescribing information listed it as Pregnancy Category C, meaning animal reproduction studies showed adverse effects and adequate human studies were lacking.

Any adolescent girl on sermorelin therapy who is sexually active should use reliable contraception. Unintended pregnancy must prompt immediate discontinuation of sermorelin and referral to an obstetrician for pregnancy management.

Lactation

No data exist on sermorelin transfer into human breast milk. GHRH is a peptide and is likely degraded in the infant's gut if present in milk. Despite that theoretical reassurance, the absence of human lactation data means clinicians should apply a precautionary approach. Breastfeeding adolescents should discuss the risk-benefit balance explicitly with their pediatric endocrinologist and obstetric provider.

Contraception Counseling

Girls who are old enough to be on sermorelin therapy and who are sexually active should receive age-appropriate contraceptive counseling per ACOG guidelines. This is a standard of care issue, not a sermorelin-specific issue, but it belongs in every medication management plan for adolescent girls. Long-acting reversible contraception (LARC) methods are generally not contraindicated alongside sermorelin.

What the Evidence Gap Means for Families

Women and girls have been historically under-represented in clinical trials across medicine, and pediatric endocrinology is not immune to this problem. The original Geref trials enrolled children with idiopathic GHD but did not always report sex-disaggregated outcomes. Whether girls respond to sermorelin at the same rate, to the same degree, and with the same side-effect profile as boys is not clearly established in the published literature.

The Endocrine Society's 2016 GHD guideline acknowledges that most GH trial data come from predominantly male cohorts, and it recommends that clinicians apply sex-specific normative references for IGF-1 and growth velocity rather than relying on combined-sex data. For girls specifically, this means using female reference ranges at every monitoring timepoint, not adjusting a male-derived target downward.

Parents of girls with GHD should feel entitled to ask their child's endocrinologist: "Are you using female-specific IGF-1 targets?" and "How will you adjust the dose as my daughter progresses through puberty?" If those questions produce vague answers, a second opinion from a pediatric endocrinologist specializing in the hypothalamic-pituitary axis is reasonable.

Adverse Effects and Safety Signals to Watch For

Sermorelin's side-effect profile in the original trials was generally mild. The most common adverse effects reported with Geref were injection-site reactions (redness, swelling, pain), occurring in approximately 16.6% of patients. Flushing, headache, and transient dizziness were less common.

The theoretical safety concern specific to GHRH analogs is antibody formation. Some children in the Geref trials developed anti-sermorelin antibodies, but these were not associated with attenuation of growth response or adverse clinical outcomes in the study period. Long-term antibody data in compounded sermorelin are essentially nonexistent.

Parents should also know that supraphysiological IGF-1 elevation, while less likely with sermorelin than with somatropin because of the self-limiting pituitary mechanism, is still possible. An IGF-1 SDS persistently above +2 warrants dose reduction. Elevated IGF-1 over the long term is one reason why some researchers have raised questions about theoretical cancer risk with GH-axis therapies, though no causal relationship has been established in pediatric GHD populations treated at standard doses.

Transitioning Off Sermorelin at Puberty Completion

Growth hormone therapy for pediatric GHD does not automatically end when linear growth stops. Children with confirmed GHD may have persistent GHD into adulthood, which carries its own metabolic, cardiovascular, and bone-density implications. The Endocrine Society recommends retesting GH status after growth plate fusion to determine whether adult GHD is present and whether ongoing GH-axis therapy is indicated.

For girls specifically, the transition off sermorelin coincides with the late-pubertal phase when estrogen is maximally driving IGF-1 production and bone accrual. A girl who completes sermorelin therapy at 16 or 17 years and then experiences estrogen withdrawal (for example, from hypothalamic amenorrhea, premature ovarian insufficiency, or over-exercising) is at compounded risk for bone deficits. Peak bone mass is established largely in the late teens and early twenties. Adequate calcium, vitamin D, and weight-bearing exercise remain non-negotiable during and after sermorelin therapy in all children, and especially in girls.

The retesting protocol for GHD transition uses the same pharmacological stimulation tests as initial diagnosis, with sex-steroid priming adjusted for the individual's hormonal status. A girl who is hypogonadal at the time of transition testing will need estrogen priming to avoid a false-positive GHD result.